Drug transporters: Gatekeepers controlling access of xenobiotics to the cellular interior

References

• Adachi Y, Suzuki H, Sugiyama Y (2001). Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharmaceut Res 18, 1660–1668.
   PubMed Web of Science ®Google Scholar
• Adachi Y, Suzuki H, Sugiyama Y (2003). Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro. Pharmaceut Res 20, 1163–1169.
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Kim IW, Sauna ZE (2006). The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharmaceut Sci 27, 392–400.
   PubMed Web of Science ®Google Scholar
• Artursson P, Karlsson J (1991). Correlation between oral-drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (CaCo-2) cells. Biochem Biophys Res Comm 175, 880–885.
   PubMed Web of Science ®Google Scholar
• Arya V, Issar M, Wang YI, Talton JD, Hochhaus G (2005). Brain permeability of inhaled corticosteroids. J Pharm Pharmacol 57, 1159–1167.
   PubMed Web of Science ®Google Scholar
• Aszalos A (2004). P-glycoprotein-based drug-drug interactions: preclinical methods and relevance to clinical observations. Arch Pharmacal Res 27, 127–135.
   PubMed Web of Science ®Google Scholar
• Avdeef A, Tsinman O (2006). PAMPA—a drug absorption in vitro model 13. Chemical selectivity due to membrane hydrogen bonding: in combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur J Pharmaceut Sci 28, 43–50.
   PubMed Web of Science ®Google Scholar
• Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W (2007). Differences in the transport of the antiepileptic drugs phenytoin, levetiracetarn, and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 52, 333–346.
   PubMed Web of Science ®Google Scholar
• Banner KH, Cattaneo C, Le Net JL, Popovic A, Collins D, Gale JD (2004). Macroscopic, microscopic, and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene. Br J Pharmacol 143, 590–598.
   PubMed Web of Science ®Google Scholar
• Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JHM, et al (2000). Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 6, 4416–4421.
   PubMed Web of Science ®Google Scholar
• Bauer B, Miller DS, Fricker G (2003). Compound profiling for p-glycoprotein at the blood-brain barrier using a microplate screening system. Pharmaceut Res 20, 1170–1176.
   PubMed Web of Science ®Google Scholar
• Becker S, Liu XR (2006). Evaluation of the utility of brain slice methods to study brain penetration. Drug Metab Dispos 34, 855–861.
   PubMed Web of Science ®Google Scholar
• Brimer C, Dalton JT, Zhu ZX, Schuetz J, Yasuda K, Vanin E, et al (2000). Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase, and MDR1/P-glycoprotein. Pharmaceut Res 17, 803–810.
   PubMed Web of Science ®Google Scholar
• Camargo F, Erickson RP, Garver WS, Hossain GS, Carbone PN, Heidenreich RA, et al (2001). Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease. Life Sci 70, 131–142.
   PubMed Web of Science ®Google Scholar
• Cao XH, Gibbs ST, Fang LY, Miller HA, Landowski CP, Shin HC, et al (2006). Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharmaceut Res 23, 1675–1686.
   PubMed Web of Science ®Google Scholar
• Chan LMS, Lowes S, Hirst BH (2004). The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharmaceut Sci 21, 25–51.
   PubMed Web of Science ®Google Scholar
• Chen CP, Hanson E, Watson JW, Lee JS (2003). P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 31, 312–318.
   PubMed Web of Science ®Google Scholar
• Chen CP, Pollack GM (1998). Altered disposition and antinociception of [D-Penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice. J Pharmacol Exp Ther 287, 545–552.
   PubMed Web of Science ®Google Scholar
• Chen CP, Pollack GM (1999). Enhanced antinociception of the model opioid peptide [D-penicillamine(2,5)] enkephalin by P-glycoprotein modulation. Pharmaceut Res 16, 296–301.
   PubMed Web of Science ®Google Scholar
• Cheng XG, Klaassen CD (2006). Regulation of mRNA expression of xenobiotic transporters by the pregnane X receptor in mouse liver, kidney, and intestine. Drug Metab Dispos 34, 1863–1867.
   PubMed Web of Science ®Google Scholar
• Chiou WL, Chung SM, Wu TC (2000). Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. Pharmaceut Res 17, 205–208.
   PubMed Web of Science ®Google Scholar
• Chu XY, Strauss JR, Mariano MA, Li J, Newton DJ, Cai XX, et al (2006). Characterization of mice lacking the multidrug resistance protein Mrp2 (Abcc2). J Pharmacol Exp Ther 317, 579–589.
   PubMed Web of Science ®Google Scholar
• Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM (2004). Expression, upregulation, and transport activity of the multidrug-resistance protein ABCG2 at the mouse blood-brain barrier. Cancer Res 64, 3296–3301.
   PubMed Web of Science ®Google Scholar
• Collett A, Tanianis-Hughes J, Carlson GL, Harwood MD, Warhurst G (2005). Comparison of P-glycoprotein-mediated drug-digoxin interactions in CaCo-2 with human and rodent intestine: relevance to in vivo prediction. Eur J Pharmaceut Sci 26, 386–393.
   PubMed Web of Science ®Google Scholar
• Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G (2004). Predicting P-glycoprotein effects on oral absorption: correlation of transport in CaCo-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharmaceut Res 21, 819–826.
   PubMed Web of Science ®Google Scholar
• Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P, et al (1989). The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 9, 1346–1350.
   PubMed Web of Science ®Google Scholar
• Dai HQ, Marbach P, Lemaire M, Hayes M, Elmquist WF (2003). Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304, 1085–1092.
   PubMed Web of Science ®Google Scholar
• de Lange ECM, de Bock G, Schinkel AH, de Boer AG, Breimer DD (1998). BBB transport and P-glycoprotein functionality using MDR1A (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123. Pharmaceut Res 15, 1657–1665.
   PubMed Web of Science ®Google Scholar
• Di L, Kerns EH, Fan K, McConnell OJ, Carter GT (2003). High-throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 38, 223–232.
   PubMed Web of Science ®Google Scholar
• Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, et al (2005). The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metabolism and Disposition 33, 165–174.
   PubMed Web of Science ®Google Scholar
• Doze P, Van Waarde A, Elsinga PH, Hendrikse NH, Vaalburg W (2000). Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier. Synapse 36, 66–74.
   PubMed Web of Science ®Google Scholar
• Eisenbraun MD, Miller RA (1999). mdr1a-encoded P-glycoprotein is not required for peripheral T cell proliferation, cytokine release, or cytotoxic effector function in mice. J Immunol 163, 2621–2627.
   PubMed Web of Science ®Google Scholar
• Eisenbraun MD, Mosley RL, Teitelbaum DH, Miller RA (2000). Altered development of intestinal intraepithelial lymphocytes in P-glycoprotein-deficient mice. Dev Compar Immunol 24, 783–795.
   PubMed Web of Science ®Google Scholar
• Endres CJ, Hsiao P, Chung FS, Unadkat JD (2006). The role of transporters in drug interactions. Eur J Pharmaceut Sci 27, 501–517.
   PubMed Web of Science ®Google Scholar
• Erickson RP, Kiela M, Devine PJ, Hoyer PB, Heidenreich RA (2002). mdr1a deficiency corrects sterility in Niemann-Pick C1 protein deficient female mice. Mol Reprod Devt 62, 167–173.
   PubMed Web of Science ®Google Scholar
• Faber KN, Muller M, Jansen PLM (2003). Drug transport proteins in the liver. Adv Drug Deliv Rev 55, 107–124.
   PubMed Web of Science ®Google Scholar
• Fricker G, Miller DS (2002). Relevance of multidrug resistance proteins for intestinal drug absorption in vitro and in vivo. Pharmacol Toxicol 90, 5–13.
   PubMedGoogle Scholar
• Frijters CMG, Tuijn CJ, Ottenhoff R, Zegers BN, Groen AK, Elferink R (1999). The role of different P-glycoproteins in hepatobiliary secretion of fluorescently labeled short-chain phospholipids. J Lipid Res 40, 1950–1957.
   PubMed Web of Science ®Google Scholar
• Gallo JM, Li SL, Guo P, Reed K, Ma JG (2003). The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res 63, 5114–5117.
   PubMed Web of Science ®Google Scholar
• Goralski KB, Acott PD, Fraser AD, Worth D, Sinal CJ (2006). Brain cyclosporin a levels are determined by ontogenic regulation of MDR1A expression. Drug Metab Disposit 34, 288–295.
   PubMed Web of Science ®Google Scholar
• Goto M, Masuda S, Saito H, Inui K (2003). Decreased expression of P-glycoprotein during differentiation in the human intestinal cell line CaCo-2. Biochemical Pharmacology 66, 163–170.
   PubMed Web of Science ®Google Scholar
• Gumbleton M, Audus KL (2001). Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J Pharmaceut Sci 90, 1681–1698.
   PubMed Web of Science ®Google Scholar
• Hamabe W, Maeda T, Fukazawa Y, Kumamoto K, Shang LQ, Yamamoto A, et al (2006). P-glycoprotein ATPase activating effect of opioid analgesics and their P-glycoprotein-dependent antinociception in mice. Pharmacol Biochem Behav 85, 629–636.
   PubMed Web of Science ®Google Scholar
• Hendrikse NH, Schinkel AH, De Vries EGE, Fluks E, Van der Graaf WTA, Willemsen ATM et al. (1998). Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 124, 1413–1418.
   PubMed Web of Science ®Google Scholar
• Hirohashi T, Suzuki H, Chu XY, Tamai I, Tsuji A, Sugiyama Y (2000). Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (CaCo-2). J Pharmacol Exp Ther 292, 265–270.
   PubMed Web of Science ®Google Scholar
• Hochman JH, Yamazaki M, Ohe T, Lin JH (2002). Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein. Curr Drug Metab 3, 257–273.
   PubMed Web of Science ®Google Scholar
• Huang LY, Hoffman T, Vore M (1998). Adenosine triphosphate-dependent transport of estradiol-17 beta(beta-D-glucuronide) in membrane vesicles by MDR1 expressed in insect cells. Hepatology 28, 1371–1377.
   PubMed Web of Science ®Google Scholar
• Huls M, Kramers C, Levtchenko EN, Wilmer MJ, Dijkman HB, Kluijtmans LA, et al (2007). P-glycoprotein-deficient mice have proximal tubule dysfunction but are protected against ischemic renal injury. Kidney Int 72, 1233–1241.
   PubMed Web of Science ®Google Scholar
• Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH (1993). Functional expression of P-glycoprotein in apical membranes of human intestinal CaCo-2 cells—kinetics of vinblastine secretion and interaction with modulators. J Biolog Chem 268, 14991–14997.
   PubMed Web of Science ®Google Scholar
• Jin M, Shimada T, Yokogawa K, Nomura M, Ishizaki J, Piao Y, et al (2006a). Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption and effect of dexamethasone in small intestine of mice. Biochem Pharmacol 72, 1042–1050.
   PubMed Web of Science ®Google Scholar
• Jin MJ, Shimida T, Yokogawa K, Nomura M, Kato Y, Tsuji A, et al (2006b). Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone. Int J Pharmaceut 309, 81–86.
   PubMed Web of Science ®Google Scholar
• Johnson DR, Finch RA, Lin ZP, Zeiss CJ, Sartorelli AC (2001). The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice. Cancer Res 61, 1469–1476.
   PubMed Web of Science ®Google Scholar
• Jonker JW, Freeman J, Bolscher E, Musters S, Alvi AJ, Titley I, et al (2005). Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells 23, 1059–1065.
   PubMed Web of Science ®Google Scholar
• Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JHM, et al (2000). Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92, 1651–1656.
   PubMed Web of Science ®Google Scholar
• Karssen AM, Meijer OC, van der Sandt ICJ, De Boer AG, De Lange ECM, De Kloet ER, (2002). The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol 175, 251–260.
   PubMed Web of Science ®Google Scholar
• Katoh M, Suzuyama N, Takeuch T, Yoshitomi S, Asahi S, Yokoi T (2006). Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J Pharmaceut Sci 95, 2673–2683.
   PubMed Web of Science ®Google Scholar
• Kawahara M, Sakata A, Miyashita T, Tami I, Tsuji A (1999). Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. Journal of Pharmaceutical Sciences 88, 1281–1287.
   PubMed Web of Science ®Google Scholar
• Keogh JP, Kunta JR (2006). Development, validation, and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharmaceut Sci 27, 543–554.
   PubMed Web of Science ®Google Scholar
• Kiesewetter DO, Jagoda EM, Kao CHK, Ma Y, Ravasi L, Shimoji K, et al (2003). Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation. Nucl Med Biol 30, 11–24.
   PubMed Web of Science ®Google Scholar
• Kim RB (2002). Transporters and xenobiotic disposition. Toxicology 181, 291–297.
   PubMed Web of Science ®Google Scholar
• Kwei GY, Alvaro RF, Chen Q, Jenkins HJ, Hop C, Keohane CA, et al (1999). Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab Disposit 27, 581–587.
   PubMed Web of Science ®Google Scholar
• Lankas GR, Cartwright ME, Umbenhauer D (1997). P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 143, 357–365.
   PubMed Web of Science ®Google Scholar
• Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR (1998). Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol 12, 457–463.
   PubMed Web of Science ®Google Scholar
• Lee G, Dallas S, Hong M, Bendayan R (2001). Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev 53, 569–596.
   PubMed Web of Science ®Google Scholar
• Leslie EM, Deeley RG, Cole SPC (2001). Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 167, 3–23.
   PubMed Web of Science ®Google Scholar
• Leusch A, Volz A, Muller G, Wagner A, Sauer A, Greischel A, et al (2002). Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice. Eur J Pharmaceut Sci 16, 119–128.
   PubMed Web of Science ®Google Scholar
• Li AP (2005). Preclinical in vitro screening assays for drug-like properties. Drug Discov Today Technol 2, 179–185.
   PubMedGoogle Scholar
• Li Q, Sai Y, Kato Y, Tamai I, Tsuji A (2003). Influence of drugs and nutrients on transporter gene expression levels in CaCo-2 and LS180 intestinal epithelial cell lines. Pharmaceut Res 20, 1119–1124.
   PubMed Web of Science ®Google Scholar
• Lin ZP, Johnson DR, Finch RA, Belinsky MG, Kruh GD, Sartorelli AC (2002). Comparative study of the importance of multidrug resistance-associated protein 1 and P-glycoprotein to drug sensitivity in immortalized mouse embryonic fibroblasts. Mol Cancer Ther 1, 1105–1114.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu YP, Powell DA, Waalkes MP, Klaassen CD (2002). Multidrug-resistance mdr1a/1b double knockout mice are more sensitive than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues. Toxicology 170, 55–62.
   PubMed Web of Science ®Google Scholar
• Lorico A, Rappa G, Finch RA, Yang D, Flavell RA, Sartorelli AC (1997). Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res 57, 5238–5242.
   PubMed Web of Science ®Google Scholar
• Lorico A, Rappa G, Flavell RA, Sartorelli AC (1996). Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Cancer Res 56, 5351–5355.
   PubMed Web of Science ®Google Scholar
• Lotsch J, Tegeder I, Angst MS, Geisslinger G (2000). Antinociceptive effects of morphine-6-glucuronide in homozygous MDR1a P-glycoprotin knockout and in wildtype mice in the hotplate test. Life Sci 66, 2393–2403.
   PubMed Web of Science ®Google Scholar
• Luker GD, Dahlheimer JL, Ostlund RE, Piwnica-Worms D (2001). Decreased hepatic accumulation and enhanced esterification of cholesterol in mice deficient in mdr1a and mdr1b P-glycoproteins. J Lipid Res 42, 1389–1394.
   PubMed Web of Science ®Google Scholar
• Luurtsema G, Molthoff CFM, Windhorst AD, Smit JW, Keizer H, Boellaard R, et al (2003). (R)- and (S)-[C-11]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl Med Biol 30, 747–751.
   PubMed Web of Science ®Google Scholar
• Mann H, Ladenheim B, Hirata H, Moran TH, Cadet JL (1997). Differential toxic effects of methamphetamine (METH) and methylenedioxymethamphetamine (MDMA) in multidrug-resistant (mdr1a) knockout mice. Brain Res 769, 340–346.
   PubMed Web of Science ®Google Scholar
• Meijer OC, de Lange ECM, Breimer DD, de Boer AG, Workel JO, de Kloet ER, (1998). Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 139, 1789–1793.
   PubMed Web of Science ®Google Scholar
• Miyata Y, Asano Y, Muto S (2002). Hyperosmotic mannitol activates basolateral NHE in proximal tubule from P-glycoprotein null mice. Am J Physiol Renal Physiol 282, F718–F729.
   PubMed Web of Science ®Google Scholar
• Mochida Y, Taguchi K, Taniguchi S, Tsuneyoshi M, Kuwano H, Tsuzuki T, et al (2003). The role of P-glycoprotein in intestinal tumorigenesis: disruption of mdr1a suppresses polyp formation in Apc(Min/+) mice. Carcinogenesis 24, 1219–1224.
   PubMed Web of Science ®Google Scholar
• Muller H, Klinkhammer W, Globisch C, Kassack MU, Pajeva IK, Wiese M (2007). New functional assay of P-glycoprotein activity using Hoechst 33342. Bioorg Med Chem 15, 7470–9.
   PubMed Web of Science ®Google Scholar
• Muller MB, Keck ME, Binder EB, Kresse AE, Hagemeyer TP, Landgraf R, Holsboer F and Uhr M (2003). ABCB1 (MDR1)-type P-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary-adrenocortical system: lmplications for affective disorder. Neuropsychopharmacology 28, 1991–1999.
   PubMed Web of Science ®Google Scholar
• Neuhoff S, Ungell AL, Zamora I, Artursson P (2003). pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharmaceut Res 20, 1141–1148.
   PubMed Web of Science ®Google Scholar
• Nezasa KI, Tian XB, Zamek-Gliszczynski MJ, Patel NJ, Raub TJ, Brouwer KLR (2006). Altered hepatobiliary disposition of 5 (and 6)-carboxy-2’,7’-dichlorofluorescein in Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice. Drug Metab Disposit 34, 718–723.
   PubMed Web of Science ®Google Scholar
• Panwala CM, Jones JC, Viney JL (1998). A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 161, 5733–5744.
   PubMed Web of Science ®Google Scholar
• Petriz J, GarciaLopez J (1997). Flow cytometric analysis of P-glycoprotein function using rhodamine 123. Leukemia 11, 1124–1130.
   PubMed Web of Science ®Google Scholar
• Pichler A, Prior JL, Piwnica-Worms D (2004). Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine. Proc Natl Acad Sci U S A 101, 1702–1707.
   PubMed Web of Science ®Google Scholar
• Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Webster LO, Barnaby RJ, et al (2004). The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters. Drug Metab Disposit 32, 722–726.
   PubMed Web of Science ®Google Scholar
• Press RR, Buckle T, Beijnen JH, van Tellingen O, (2006). The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. Cancer Chemother Pharmacol 57, 819–825.
   PubMed Web of Science ®Google Scholar
• Resta-Lenert S, Smitham J, Barrett KE (2005). Epithelial dysfunction associated with the development of colitis in conventionally housed mdr1a(-/-) mice. Am J Physiol Gastroint Liver Physiol 289, G153–G162.
   PubMed Web of Science ®Google Scholar
• Salama NN, Kelly EJ, Bui T, Ho RJY (2005). The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice. J Pharmaceut Sci 94, 1216–1225.
   PubMed Web of Science ®Google Scholar
• Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y (2004). Differential involvement of multidrug resistance-associated protein 1 and P-glycoprotein in tissue distribution and excretion of grepafloxacin in mice. J Pharmacol Exp Ther 310, 648–655.
   PubMed Web of Science ®Google Scholar
• Schellens JHM, Malingre MM, Kruijtzer CMF, Bardelmeijer HA, van Tellingen O, Schinkel AH, Beijnen JH, (2000). Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharmaceut Sci 12, 103–110.
   PubMed Web of Science ®Google Scholar
• Schinkel AH (1997). The physiological function of drug-transporting P-glycoproteins. Sem Cancer Biol 8, 161–170.
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Mayer U, Wagenaar E, Mol C, vanDeemter L, Smit JJM, et al (1997). Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A 94, 4028–4033.
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Mol C, Wagenaar E, Vandeemter L, Smit JJM, Borst P (1995). Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 31A, 1295–1298.
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Smit JJM, Vantellingen O, Beijnen JH, Wagenaar E, Vandeemter L, et al (1994). Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain-barrier and to increased sensitivity to drugs. Cell 77, 491–502.
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Wagenaar E, Mol C, vanDeemter L (1996). P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97, 2517–2524.
   PubMed Web of Science ®Google Scholar
• Schuetz EG, Umbenhauer DR, Yasuda K, Brimer C, Nguyen L, Relling MV, et al (2000). Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol Pharmacol 57, 188–197.
   PubMed Web of Science ®Google Scholar
• Shaik N, Giri N, Pan G, Elmquist WF (2007). P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos 35, 2076–2085.
   PubMed Web of Science ®Google Scholar
• Sharma RP, Bhandari N, Tsunoda M, Riley RT, Voss KA, Meredith FI (2000). Fumonisin toxicity in a transgenic mouse model lacking the mdr 1a/1b P-glycoprotein genes. Environ Toxicol Pharmacol 8, 173–182.
   PubMed Web of Science ®Google Scholar
• Sharma V, Prior JL, Belinsky MG, Kruh GD, Piwnica-Worms D (2005). Characterization of a Ga-67/Ga-68 radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier. J Nucl Med 46, 354–364.
   PubMed Web of Science ®Google Scholar
• Shirasaka Y, Sakane T, Yamashita S (2008). Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci 97, 553–565.
   PubMed Web of Science ®Google Scholar
• Sills GJ, Kwan P, Butler E, de Lange ECM, van den Berg DJ, Brodie MJ (2002). P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilep Behav 3, 427–432.
   PubMed Web of Science ®Google Scholar
• Smit JJM, Schinkel AH, Elferink R, Groen AK, Wagenaar E, Vandeemter L, et al., (1993). Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver-disease. Cell 75, 451–462.
   PubMed Web of Science ®Google Scholar
• Smit JW, Schinkel AH, Muller M, Weert B, Meijer DKF (1998). Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption. Hepatology 27, 1056–1063.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, vanAsperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, et al (1997). Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 94, 2031–2035.
   PubMed Web of Science ®Google Scholar
• Stephens RH, O’Neill CA, Bennett J, Humphrey M, Henry B, Rowland M, Warhurst G (2002). Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice. Br J Pharmacol 135, 2038–2046.
   PubMed Web of Science ®Google Scholar
• Stride BD, Cole SPC, Deeley RG (1999). Localization of a substrate specificity domain in the multidrug resistance protein. J Biolog Chem 274, 22877–22883.
   PubMed Web of Science ®Google Scholar
• Stride BD, Grant CE, Loe DW, Hipfner DR, Cole SPC,andandDeeley RG (1997). Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol 52, 344–353.
   PubMed Web of Science ®Google Scholar
• Sugano K, Nabuchi Y, Machida M, Aso Y (2003). Prediction of human intestinal permeability using artificial membrane permeability. Int J Pharmaceut 257, 245–251.
   PubMed Web of Science ®Google Scholar
• Sugihara N, Toyama K, Okamoto T, Kadowaki M, Terao K, Furuno K (2007). Effects of benzo(e)pyrene and benzo(a)pyrene on P-glycoprotein-mediated transport in CaCo-2 cell monolayer: a comparative approach. Toxicol In Vitro 21, 827–834.
   PubMed Web of Science ®Google Scholar
• Summerfield SG, Stevens AJ, Cutler L, Osuna MD, Hammond B, Tang SP, et al (2006). Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharmacol Exp Ther 316, 1282–1290.
   PubMed Web of Science ®Google Scholar
• Sun HY, Dai HQ, Shaik N, Elmquist WF (2003). Drug efflux transporters in the CNS. Adv Drug Deliv Rev 55, 83–105.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Sugiyama Y (2000). Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharmaceut Sci 12:3–12.
   PubMed Web of Science ®Google Scholar
• Tahara H, Kusuhara H, Fuse E, Sugiyama Y (2005). P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab Dispos 33, 963–968.
   PubMed Web of Science ®Google Scholar
• Taipalensuu J, Tavelin S, Lazorova L, Svensson AC, Artursson P (2004). Exploring the quantitative relationship between the level of MDR1 transcript, proteinand function using digoxin as a marker of MDR1-dependent drug efflux activity. Eur J Pharmaceut Sci 21, 69–75.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Yoshitomi S, Higuchi T, Ikemoto K, Niwa SI, Ebihara T, et al (2006). Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharmaceut Res 23, 1460–1472.
   PubMed Web of Science ®Google Scholar
• Tamai I, Yamashita J, Kido Y, Ohnari A, Sai Y, Shima Y, et al (2000). Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J Pharmacol Exp Ther 295, 146–152.
   PubMed Web of Science ®Google Scholar
• Tang-Wai DF, Kajiji S, Dicapua F, Degraaf D, Roninson IB, Gros P (1995). Human (Mdr1) and mouse (Mdr1, Mdr3) P-glycoproteins can be distinguished by their respective drug-resistance profiles and sensitivity to modulators. Biochemistry 34, 32–39.
   PubMed Web of Science ®Google Scholar
• Thompson SJ, Koszdin K, Bernards CM (2000). Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 92, 1392–1399.
   PubMed Web of Science ®Google Scholar
• Tian X, Li J, Zamek-Gliszczynski MJ, Bridges AS, Zhang P, Patel NJ, et al (2007). Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice. Antimicrob Agents Chemother 51, 3230–3234.
   PubMed Web of Science ®Google Scholar
• Tian X, Zamek-Gliszczynski MJ, Li J, Bridges AS, Nezasa K, Patel NJ, et al (2008). Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab Dispos 36, 61–64.
   PubMed Web of Science ®Google Scholar
• Uhr M, Grauer MT (2003). abcblab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatric Res 37, 179–185.
   PubMed Web of Science ®Google Scholar
• Uhr M, Grauer MT, Yassourrdis A and Ebinger M (2007). Blood-brain barrier penetration and pharmacokinetics of amitryptiline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. J. Psychiatric Res 41, 179–188.
   PubMed Web of Science ®Google Scholar
• Uhr M, Grauer MT, Holsboer F (2003). Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biolog Psychiatry 54, 840–846.
   PubMed Web of Science ®Google Scholar
• Uhr M, Holsboer F, Muller MB (2002). Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone, and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J Neuroendocrinol 14, 753–759.
   PubMed Web of Science ®Google Scholar
• Uhr M, Steckler T, Yassouridis A, Holsboer F (2000). Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to Mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22, 380–387.
   PubMed Web of Science ®Google Scholar
• Umbenhauer DR, Lankas GR, Pippert TR, Wise LD, Cartwright ME, Hall SJ, et al (1997). Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol Appl Pharmacol 146, 88–94.
   PubMed Web of Science ®Google Scholar
• van Asperen J, van Tellingen O, Beijnen JH, (2000). The role of MDR1A P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab Dispos 28, 264–267.
   PubMed Web of Science ®Google Scholar
• van de Wetering K, Zelcer N, Kuil A, Feddema W, Hillebrand M, Vlaming ML et al. (2007). Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides. Mol Pharmacol 72, 387–394.
   PubMed Web of Science ®Google Scholar
• van Tellingen O, Buckle T, Jonker JW, van der Valk MA, Beijnen JH, (2003). P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo. Br J Cancer 89, 1776–1782.
   PubMed Web of Science ®Google Scholar
• Vlaming MLH, Mohrmann K, Wagenaar E, de Waart DR, Elferink R, Lagas JS et al. (2006). Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318, 319–327.
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Granda BW, Grassi JM, Perloff MD, Vishnuvardhan D, Greenblatt DJ, (2004). Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice. Drug Metab Dispos 32, 800–804.
   PubMed Web of Science ®Google Scholar
• Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman ANR, Smith DA (2005). Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 33, 587–595.
   PubMed Web of Science ®Google Scholar
• Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL (2004). Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology 173, 132–138.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Onuki R, Yamashita S, Taira K, Sugiyama Y (2005). Construction of a functional transporter analysis system using MDR1 knockdown CaCo-2 cells. Pharmaceut Res 22, 1287–1293.
   PubMed Web of Science ®Google Scholar
• Watchko JF, Daood MJ, Hansen TWR (1998). Brain bilirubin content is increased in P-glycoprotein-deficient transgenic null mutant mice. Pediatric Res 44, 763–766.
   PubMed Web of Science ®Google Scholar
• Wijnholds J, de Lange ECM, Scheffer GL, van den Berg DJ, Mol C, van der Valk M et al. (2000). Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 105, 279–285.
   PubMed Web of Science ®Google Scholar
• Wijnholds J, Evers R, vanLeusden M (1997). Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med 3, 1275–1279.
   PubMed Web of Science ®Google Scholar
• Xie YX, Liu J, Liu YP, Klaassen CD, Waalkes MP (2004). Toxicokinetic and genomic analysis of chronic arsenic exposure in multidrug-resistance mdr1a/1b(-/-) double knockout mice. Mol Cell Biochem 255, 11–18.
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Yano I, Saito H, Inui KI (2002). Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. J Pharmac Exp Ther 300, 1063–1069.
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Neway WE, Ohe T, Chen IW, Rowe JF, Hochman JH, et al (2001). In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmac Exp Ther 296, 723–735.
   PubMed Web of Science ®Google Scholar
• Yokogawa K, Takahashi M, Tamai I, Konishi H, Nomura M, Moritani S, et al (1999). P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. Pharmaceut Res 16, 1213–1218.
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Tallman MN, Brouwer KLR (2006a). Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharmaceut Sci 27, 447–486.
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski MJ, Nezasa KI, Tian XB, Kalvass JC, Patel NC, Raub TJ, et al (2006b). The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol Pharmacol 70, 2127–2133.
   PubMed Web of Science ®Google Scholar
• Zhang DW, Cole SPC, Deeley RG (2001). Identification of an amino acid residue in multidrug resistance protein 1 critical for conferring resistance to anthracyclines. J Biolog Chem 276, 13231–13239.
   PubMed Web of Science ®Google Scholar
• Zhang SZ, Wang XD, Sagawa K, Morris ME (2005). Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Drug Metab Dispos 33, 341–348.
   PubMed Web of Science ®Google Scholar